Shots:
• The companies enter into a collaboration to conduct a study assessing the combination of Innovent's Tyvyt (sintilimab injection) and Sirnaomics' RNAi drug candidate STP705 (cotsiranib) in advanced cancers including Hepatocellular Carcinomas (HCC)
• The agreement will be the first example evaluating the combination of RNAi drug candidate- cotsiranib & immune checkpoint Ab- sintilimab to treat liver cancers
• Tyvyt is an immunoglobulin G4 mAb involved in binding PD-1 molecules and further blocks the interaction of the PD-1/ PD-L1 pathway and is jointly developed by Innovent and Lilly. STP705 is a siRNA therapeutic with the ability of dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-β1 and COX-2 gene expression

Click here to read full press release/ article

Ref: PRNewswire | Image: Innovent